Pharmacological vitreolysis

Details Pharmacological vitreolysis Pharmacological vitreolysis

2003-12-05

2009-06-16

Lankford, L Blaine (Department: 1651)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C424S094100, C424S094630, C424S094600, C604S290000

Reexamination Certificate

active

07547435

ABSTRACT:
Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

REFERENCES:
patent: 2624691 (1953-01-01), Loomis
patent: 3234106 (1966-02-01), Hink
patent: 3950513 (1976-04-01), Jensen
patent: 4774087 (1988-09-01), Wu et al.
patent: 4820516 (1989-04-01), Sawyer et al.
patent: 5288489 (1994-02-01), Reich et al.
patent: 5292509 (1994-03-01), Hageman
patent: 5304118 (1994-04-01), Trese et al.
patent: 5637299 (1997-06-01), McDonagh
patent: 5722428 (1998-03-01), Kaplan et al.
patent: 5866120 (1999-02-01), Karageozian et al.
patent: 6051698 (2000-04-01), Janjic et al.
patent: 6183692 (2001-02-01), Trese et al.
patent: 6207066 (2001-03-01), Trese et al.
patent: 6355243 (2002-03-01), Novokhatny
patent: 6462071 (2002-10-01), Castillejos
patent: 6585972 (2003-07-01), Peyman
patent: 6596725 (2003-07-01), Peterson et al.
patent: 6610292 (2003-08-01), Karageozian et al.
patent: 6733750 (2004-05-01), Peyman
patent: 6787135 (2004-09-01), Trese
patent: 2002/0042652 (2002-04-01), Peyman
patent: 2002/0139378 (2002-10-01), Trese et al.
patent: 2002/0192794 (2002-12-01), Dadd
patent: 2003/0012778 (2003-01-01), Zimmerman et al.
patent: 2003/0026798 (2003-02-01), Zimmerman
patent: 2003/0113313 (2003-06-01), Peyman
patent: 2003/0147877 (2003-08-01), Trese et al.
patent: 2003/0175263 (2003-09-01), Trese et al.
patent: 2004/0081643 (2004-04-01), Peyman
patent: 2006/0257391 (2006-11-01), Bartels
patent: 2007/0128182 (2007-06-01), Bartels
patent: 2007/0141043 (2007-06-01), Bartels
patent: 2008/0008698 (2008-01-01), Bartels
patent: 2008/0050356 (2008-02-01), Pakola
patent: 2008/0095753 (2008-04-01), Pakola
patent: 985498 (1965-03-01), None
patent: WO 98/52602 (1998-05-01), None
patent: WO 02/50290 (2002-06-01), None
patent: WO0250290 (2002-06-01), None
patent: WO-2004/052228 (2004-06-01), None
Tanaka et al. 2000. Pharmacological vitrectomy. Semin. Ophthalmol. 15(1):51-61.
Berman et al., “Evidence for a role of the plasminogen activator-plasmin system in corneal ulceration,”Invest Ophthalmol Vis Sci., 19(10):1204-21 (Oct. 1980).
Castellino and Powell, “Human plasminogen,”Methods Enzymol., 80 Pt C:365-78 (1981).
Castellino et al., “Kringle domains of human plasminogen,” Ciba Found. Symp., 212:46-60 (1997).
Castellino et al., “The existence of independent domain structures in human Lys77-plasminogen,”J Biol Chem., 256(10):4778-82 (May 25, 1981).
Chow et al., “Successful Closure of Traumatic Macular Holes,”Retina, 19(5):405-409 (1999).
Forsgren et al., “Molecular cloning and characterization of a full-length cDNA clone for human plasminogen,”FEBS Lett., 213(2):254-60 (Mar. 23, 1987).
Gandorfer et al., Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy,Br. J. Opthalmology, 85:6-10 (2001).
Gandorfer et al., “Vitreoretinal Morphology of Plasmin-Treated Human Eyes,”Am. J. Opthalmol., 133(1):156-159 (Jan. 2002).
Gandorfer et al., “Plasmin-assisted vitrectomy eliminates cortical vitreous remnants,”Eye, 16:95-97 (2002).
Hikichi et al., Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous,Retina, 19:55-58 (1999).
Immonen et al., “Plasmin in subretinal fluid,”Acta Ophthalmol. (Copenh.), 66(6):647-51 (Dec. 1988).
Immonen et al., “Tissue-type plasminogen activator in subretinal fluid,”Curr Eye Res., 8(3):249-52 (Mar. 1989).
Lasters et al., “Enzymatic properties of phage-displayed fragments of human plasminogen,”Eur J Biochem., 244(3):946-52 (Mar. 15, 1997).
Lijnen et al., “On the role of the carbohydrate side chains of human plasminogen in its interaction with alpha 2-antiplasmin and fibrin,”Eur. J. Biochem., 120(1):149-54 (Nov. 1981).
Liotta et al., “Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane,”Cancer Res., 41(11 Pt 1):4629-36 (Nov. 1981).
Mandl, “Bacterial collagenases and their clinical applications,”Arzneimittelforschung, 32(10a):1381-4 (1982).
Margherio et al., Plasmin enzyme assisted vitrectomy in traumatic pediatric macular holes,Ophthalmology, 105:1617-1620 (1998).
Moorhead et al., “Bacterial collagenase. Proposed adjunct to vitrectomy with membranectomy,”Arch. Ophthalmol.,;98(10):1829-39 (Oct. 1980).
Moorhead et al., “Enzyme-assisted vitrectomy with bacterial collagenase. Time course and toxicity studies,”Arch. Ophthalmol., 101(2):265-74 (Feb. 1983).
Moorhead and Radtke, “Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies,”Retina, 5(2):98-100 (Spring-Summer, 1985).
O'Neill, R. and Shea, M., “The effects of bacterial collagenase in rabbit vitreous,”Can J Ophthalmol., 8(2):366-70 (Apr. 1973).
Sottrup-Jensen et al., in Atlas of Protein Sequence and Structure, vol. 5, suppl. 3, p. 91, eds. Dayhoff (National Biomedical Research Foundation, Silver Spring, MD).
Tanaka and Qui, “Pharmacological Vitrectomy,” Sem Opthalmol. 15(1):51-61 (Mar. 2000).
Tezel et al., “Posterior vitreous detachment with dispase,”Retina, 18(1):7-15 (1998).
Trese et al., “A new approach to stage 3 macular holes,”Ophthalmology, 107(8):1607-11 (Aug. 2000).
Trese et al., Annual Meeting of the Association for Research in Vision and Opthalmology, Fort Lauderdale (IOVS), Florida; May 9-14, 1999.
Van Setten et al., “Plasmin and plasminogen activator activities in tear fluid during corneal wound healing after anterior keratectomy,”Curr Eye Res., 8(12):1293-8 (Dec. 1989).
Verstraeten et al., “Pharmacologic Induction of Posterior Vitreous Detachment in the Rabbit,”Arch Ophthalmol., 111:849-854 (Jun. 1993).
Williams et al., “Autologous plasmin enzyme in the surgical management of diabetic retinopathy,”Ophthalmology, 108(10):1902-5; discussion 1905-6 (Oct. 2001).
Xiaoxin Li et al., “Posterior vitreous detachment with plasmin in the isolated human eye,”Graefe's Arch Clin Exp Ophthalmol, 240:56-62 (2002).
Xu et al., “Permeability and Diffusion in Vitreous Humor: Implications for Drug Delivery,”Pharm. Res., 17(6):664-669 (2000).
Gandorfer, et al., “Posterior Vitreous Detachment Induced by Microplasmin,”Investigative Opthalmology&Visual Science, 45(2):641-647 (Feb. 2004).
Sakuma, et al., “Safety ofIn VivoPharmacologic Vitreolysis with Recombinant Microplasmin In Rabbit Eyes,”IOVS, 46(9):3295-3299 (Sep. 2005).
Trese, “Enzymatic-Assisted Vitrectomy,”Eye, 16(4):365-368 (Jul. 2002).
European Search Report EP 03 81 2818.
Wiman and Collen,“Molecular Mechanism of physiological fibrinolysis,”Nature272(6):549-550, 1978.
Wiman and Wallen, “The specific interaction between plasminogen and fibrin: A physiological role of the lysine binding site in plasminogen,”Thrombosis Research, 1:213-222, 1977.
Komorowicz, et al., “Fibrinolysis with Des-Kringle Derivatives of Plasmin and Its Modulation by Plasma Protease Inhisitors,”Biochemistry37:9112-9118, 1998.
Chow, et al., “Successful Closure of Traumatic Macular Holes”, Retina, 19(5)

Affiliated with

Also associated with

Rating

Pharmacological vitreolysis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmacological vitreolysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacological vitreolysis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4146323